Sheet	+	of <u>3</u>	_
Application No. 09/821,719	OHO	S	RE
	ENTE	EP 1	Ç
Group Art Unit	교	0	711

1645

**Information Disclosure Statement** by Applicant (Use several sheets if necessary)

abstitute Form PTO-1449

U.S. Department of Commerce

Patent and Trademark Office

U.S. Patent Documents

Attorney's Docket No.

John A. Lust, et al.

07039-260001

March 29, 2001

Applicant

Filing Date

				U.S. I ate	iii Documenta			9 (
E	xaminer Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	WY	AA	5,470,952	11/28/95	Stahl et al.			
		AB	5,844,099	12/01/98	Stahl et al.			

	Foreig	n Patent Doo	uments or Pu	blished Foreign	Patent A	Application	ns	
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID d	Number	Date	Patent Office	Class	Subclass	Yes	No
W	AC							

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Desig. Initial ID / Document		Document			
mo	AD /	Alexanian and Dimopoulos, "The Treatment of Multiple Myeloma," New Engl. J. Med., 1994, 330(7):484-489			
	AE	Balkwill (ed.), Cytokines – A Practical Approach, 1991, IRL Press at Oxford University Press, Oxford, pp. 311-312			
	AF V	Bataille et al., "Serum Levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias," J. Clin. Invest., 1989, 84:2008-2011			
	AG /	Bataille et al., "Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma," <u>Blood</u> , 1995, 86(2):685-691			
	AH ,	Carter et al., "The role of interleukin-1 and tumour necrosis factor-α in human multiple myeloma," Br. J. Haematol., 1990, 74:424-431			
	AI	Carter et al., "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein," Nature, 1990, 344:633-638			
	AJ	Costes et al., "Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production," Br. J. Haematol., 1998, 103:1152-1160			
	AK	Dinarello et al., "Anticytokine Strategies in the Treatment of the Systemic Inflammatory Resposne Syndrome," JAMA, 1993, 269(14):1829-1835			
	AL A	Dinarello, "Biologic Basis for Interleukin-1 in Disease," Blood, 1996, 87(6):2095-2147			
	AM	Dinarello and Thompson, "Blocking IL-1: interleukin 1 receptor antagonist <i>in vivo</i> and <i>in vitro</i> ," Immunol, Today, 1991, 12(11):404-410			
Donovan et al., "Contrast in cytokine expression between patients with monoclonal gamm		Donovan et al., "Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma," <u>Leukemia</u> , 1998, 12:593-600			
Eisenberg et al., "Primary structure and functional expr		numan interleukin-1 receptor antagonist, <u>Nature</u> , 1990, 343:341-346			
		Greipp and Lust, "Pathogenetic Relation Between Monoclonal Gammopathies of Undetermined Significance and Multiple Myeloma," Stem Cells, 1995, 13(Suppl. 2):10-21			
		Greipp and Witzig, "Biology and treatment of myeloma," Curr. Opn. Oncol., 1996, 8:20-27			
1	AR	Grigorieva et al., "The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone," <a href="Exp. Hematol.">Exp. Hematol.</a> , 1998, 26:597-603			

Examiner Signature		onsidered
of which	У 1 /	/lu/VV
1 0 0	0	/ ·
<b>EXAMINER: Initials citation considere</b>	d. Draw line through citation if not in conf	ormance and not considered. Include copy of this form with
next communication to applicant.		

Sheet	2 bf	3

				~~~~	,	_
Substitute Form PTO-1449  (Modified U.S. Department of Corporation Patent and Trademark		s Docket No. -260001	Application No. 09/821,719	H CE,	SE	
Information Disclosure Statement SEP 0 7 2001 55 by Applicant (Usateveral sheets if necessary)	Applicant John A	Lust, et al.		VTER	P 1 (	CE
(Use several sheets if necessary)	Filing Dat March	te 29, 2001	Group Art Unit 1645	1600/2	200	$\overline{\mathbf{x}}$
TRADE				<u> </u>		四

d TRA		<u> </u>
	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig.	Document
\M\h	AS	Hannum et al., "Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor," Nature, 1990, 343:336-340
11,0	AT .	Hawley et al., "Expression of Retrovirally Transduced IL-1α in IL-6-Dependent B Cells: A Murine Model of Aggressive Multiple Myeloma," Growth Factors, 1991, 5:327-338
	AU /	Hilbert et al., "Interleukin 6 Is Essential for In Vivo Development of B Lineage Neoplasms," J. Exp. / Med., 1995, 182:243-248
	AV ,	Howard et al., "IL-1-Converting Enzyme Requires Aspartic Acid Residues for Processing of the IL-1β Precursor at Two Distinct Sites and Does Not Cleave 31-kDa IL-1α," <u>J. Immunol.</u> , 1991, 147(9):2964-2969
	AW	Kawano et al., "Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas," Nature, 1988, 332:83-85
	AX V	Kishimoto, "The Biology of Interleukin-6," <u>Blood</u> , 1989, 74:1-10
	AY	Klein et al., "Paracrine Rather Than Autocrine Regulation of Myeloma-Cell Growth and Differentiation by Interleukin-6," Blood, 1989, 73(2):517-526
	AZ 🗸	Klein et.al., "Inhibiting IL-6 in Human Multiple Myeloma," <u>Curr. Topics Microbiol. Immunol.</u> , 1992, 182:237-244
	AAA	Kyle, "Newer Approaches to the Management of Multiple Myeloma," Cancer, 1993, 72(11):3489-3494
	ABB	Kyle, "Benign" Monoclonal Gammopathy – After 20 to 35 Years of Follow-up, Mayo Clin. Proc., 1993, 68:26-36
		Kyle and Greipp, "Smoldering Multiple Myeloma," New Engl. J. Med., 1980, 302:1347-1349
	ADD V	Kyle and Lust, "Monoclonal Gammopathies of Undetermined Significance," <u>Sem. Hematol.</u> , 1989, 26(3):176-200
	AEE	Lacy et al., "Comparison of Interleukin-1ß Expression by In Situ Hybridization in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma," <u>Blood</u> , 1999, 93:300-305
l,	Arr	Lust and Donovan, "The Role of Interleukin-1β in the Pathogenesis of Multiple Myeloma,"  /Hematology/Oncology Clinics of North America, 1999, 13(6):1117-11125
	AGG	March et al., "Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs," Nature, 1985, 315:641-647
	AHH	Nagata et al., "Interleukin 1 Autocrine Growth System in Human Multiple Myeloma," Jpn. J. Clin.  Oncol., 1991, 21:22-29
	AII	Oken et al., "Comparison of Melphalan and Prednisone with Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Multiple Myeloma," <u>Cancer</u> , 1997, 79:1561-1567
	AJJ	Parker et al., "Cancer Statistics, 1996," <u>CA – A Cancer Journal for Clinicians</u> , 1996, 46:5-27
	AKK	Portier et al., "In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma," Eur. J. Immunol., 1991, 21:1759-1762
7 9	ALL	Schwab et al., "Characterization of an Interleukin-6-Mediated Autocrine Growth Loop in the Human Multiple Myeloma Cell Line, U266," <u>Blood</u> , 1991, 77(3):587-593
V	AMM	Sleath et al., "Substrate Specificity of the Protease That Processes Human Interleukin-1β," <u>J. Biol.</u> <u>Chem.</u> , 1990, 265(24):14526-14528

Examiner Signature	Date Considered
Com HM	6/1011
EXAMINER: Initials citation considered. Draw line through citation if no	ot in conformance and not considered. Include copy of this form with
next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-260001	Application No. 09/821,719
\ h A.	closure Statement oplicant	Applicant John A. Lust, et al.	
SEP 0 7 2001 (Use several st	neets if necessary)	Filing Date March 29, 2001	Group Art Unit 1645
EAT - TO LOEN		<del>"</del>	

TRAIL	Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner	Desig.					
Initial	ID /	Document				
λ	.V	Tanihara et al., "A Synthetic Peptide Corresponding to 86-93 of the Human Type I IL-1 Receptor				
MX	ANN	Binds Human Recombinant IL-1 (α and β) and Inhibits IL-1 Actions in vitro and in vivo," Biochem.				
אוןע <i>ו</i>		Biophys. Res. Comm., 1992, 188(2):912-920				
	AOO	Torcia et al., "Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow				
	AOO	cells by different interleukin-1 inhibitors," Exp. Hematol., 1996, 24:868-874				
	APP V	Yamamoto et al., "Production of Interleukin 1β, a Potent Bone Resorbing Cytokine, by Cultured				
(1)	APP •	Human Myeloma Cells," <u>Cancer Res.</u> , 1989, 49:4242-4246				
1		Zhang et al., "Interleukin-6 Is a Potent Myeloma-Cell Growth Factor in Patients With Aggressive				
J	AQQ	Multiple Myeloma," Blood, 1989, 74:11-13				

Examiner Signature

Date Considered

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.